深圳大学王东团队报道了第二种近红外聚集诱导发射活性金属试剂，用于乳腺癌特殊光治疗。相关研究成果发表在2025年1月7日出版的《美国化学会杂志》。

开发具有第二近红外（NIR-II）聚集诱导发射（AIE）的小分子有机光治疗剂，对于癌症的光触发诊断成像，和通过激发态能量耗散的良好平衡的同步原位治疗至关重要。

该文中，研究人员通过将AIE活性N^N辅助配体与三价铱离子配位，开发了一种多功能铱（III）配合物。所得复合物DPTPzIr在吸收/发射波长、活性氧（ROS）产生，和光热转换方面明显优于其母体配体，这同时赋予DPTPzIr-纳米粒子与商业808nm激光匹配的吸收峰、相比先前报道的AIE-铱（III）复合物最长的NIR-II发射峰（1100nm以上）、增强的I型ROS产生和高达60.5%的光热转换效率。

因此，DPTPzIr纳米颗粒在荷瘤小鼠乳腺癌的多模式图像引导，光动力学治疗-光热治疗中表现良好，能够实现精确的肿瘤诊断，和具有高生物相容性的完全消融。

该工作为开发先进的光疗药物，提供了一个简单、可行和有效的范例。

附：英文原文

Title: The Midas Touch by Iridium: A Second Near-Infrared Aggregation-Induced Emission-Active Metallo-Agent for Exceptional Phototheranostics of Breast Cancer

Author: Caifa You, Leyuan Tian, Jun Zhu, Lei Wang, Ben Zhong Tang, Dong Wang

Issue&Volume: January 7, 2025

Abstract: Developing small organic molecular phototheranostic agents with second near-infrared (NIR-II) aggregation-induced emission (AIE) is paramount for the phototriggered diagnostic imaging and synchronous in situ therapy of cancer via an excellent balance of the excited states energy dissipations. In this study, a multifunctional iridium(III) complex is exploited by the coordination of an AIE-active N^N ancillary ligand with a trivalent iridium ion. The resultant complex DPTPzIr significantly outperforms its parent ligand in terms of absorption/emission wavelengths, reactive oxygen species (ROS) production, and photothermal conversion, which simultaneously endow DPTPzIr nanoparticles with matched absorption peak to commercial 808 nm laser, the longest NIR-II emission peak (above 1100 nm) among those previously reported AIE iridium(III) complexes, potentiated type-I ROS generation, and as high as 60.5% of photothermal conversion efficiency. Consequently, DPTPzIr nanoparticles perform well in multimodal image-guided photodynamic therapy-photothermal therapy for breast cancer in tumor-bearing mice, enabling precise tumor diagnosis and complete ablation with high biocompatibility. Our present work provides a simple, feasible, and effective paradigm for the development of advanced phototheranostic agents.

DOI: 10.1021/jacs.4c15150

Source: https://pubs.acs.org/doi/abs/10.1021/jacs.4c15150